Skip to content
Screener

Veracyte VCYT Operating Lease Liabilities

Operating Lease Liabilities at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
$84.1M-3.8%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$23.37M-3.1%
Castle Biosciences logo
Castle BiosciencesCSTL
$25.12M+78.8%
Personalis, Inc. logo
Personalis, Inc.PSNL
$31.02M-9.1%
Guardant Health logo
Guardant HealthGH
$173.06M+7.9%
Natera, Inc. logo
Natera, Inc.NTRA
$143.07M+39.3%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.71B+97.6%
Enterprise value$3.48B+104%
P/E42.2×-29.1×
P/S6.9×+2.9×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Veracyte’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031
Line itemMarch 31, 2026December 31, 2025
Total current liabilities56,11559,937
Deferred tax liabilities636646
Acquisition-related contingent consideration, net of current portion257257
Operating lease liabilities, net of current portion34,98635,603
Total liabilities91,99496,443
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Veracyte's operating lease liabilities?
Veracyte (VCYT) reported operating lease liabilities of $34.99M in Q1 2026.
How has Veracyte's operating lease liabilities changed year-over-year?
Veracyte's operating lease liabilities decreased by 18.8% year-over-year, from $43.09M to $34.99M.
What is the long-term trend for Veracyte's operating lease liabilities?
Over 5 years (2020 to 2025), Veracyte's operating lease liabilities has grown at a 29.1% compound annual growth rate (CAGR), from $9.92M to $35.6M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Veracyte's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude